SubHero Banner

Tabrecta (capmatinib) – New orphan drug approval

May 6, 2020 - The FDA announced the approval of Novartis’ Tabrecta (capmatinib), for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

Download PDF